Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 1, 2003, Pages 117-128

  Villeneuve, Lyne ^a   Girard, Hugo ^a   Fortier, Louis Charles ^a   Gagné, Jean Francois ^a   Guillemette, Chantal ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; FLAVOPIRIDOL; GLUCURONOSYLTRANSFERASE; IRINOTECAN;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BIOTRANSFORMATION; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; DRUG GLUCURONIDATION; DRUG METABOLISM; EMBRYO; ENZYME SUBSTRATE; ETHNIC GROUP; EXON; HETEROZYGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METABOLISM; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICITY;

EID: 0141519502     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.054072     Document Type: Article

References (40)

1. Albert C, Vallee M, Beaudry G, Belanger A, and Hum DW (1999) The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology 140:3292-3302.
2. Ando M, Ando Y, Sekido Y, Shimokata K, and Hasegawa Y (2002) Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 93:591-597.
3. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, and Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926.
4. Ciotti M, Basu N, Brangi M, and Owens IS (1999) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 260:199-202.
5. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
6. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, et al. 1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [see comments]. Lancet 352:1413-1418.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, and Alakl M (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047.
8. Faucher M, Anctil JL, Rodrigue MA, Duchesne A, Bergeron D, Blondeau P, Cote G, Dubois S, Bergeron J, Arseneault R, et al. (2002) Founder TIGR/myocilin mutations for glaucoma in the Quebec population. Hum Mol Genet 11:2077-2090.
9. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, and Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617.
10. Gschaidmeier H and Bock KW (1994) Radiation inactivation analysis of microsomal UDP-glucuronosyltransferases catalysing mono- and diglucuronide formation of 3, 6-dihydroxybenzo(a)pyrene and 3, 6-dihydroxychrysene. Biochem Pharmacol 48:1545-1549.
11. Guillemette C (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136-158.
12. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, and Housman DE (2000) Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644.
13. Guillemette C and Villeneuve L (2003) Substrate-dependent impact of a novel exon 1 polymorphism in the human UGT1A9 gene, in Drug Metabolism Review - Biotransformation and Disposition of Xenobiotics. Abstracts from the 8th European Meeting of the International Society for the Study of Xenobiotics (ISSX) (Hinson JA ed), Dijon, France, April 27-May 1, vol. 35, Suppl 1, p. 59.
14. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, and Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725.
15. Hagenauer B, Salamon A, Thalhammer T, Kunert O, Haslinger E, Klingler P, Senderowicz AM, Sausville EA, and Jager W (2001) In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos 29:407-414.
16. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, and Sawada J (2001) Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 31:687-699.
17. Ishii Y, Miyoshi A, Watanabe R, Tsuruda K, Tsuda M, Yamaguchi-Nagamatsu Y, Yoshisue K, Tanaka M, Maji D, Ohgiya S, et al. (2001) Simultaneous expression of guinea pig UDP-glucuronosyltransferase 2B21 and 2B22 in COS-7 cells enhances UDP-glucuronosyltransferase 2B21-catalyzed morphine-6-glucuronide formation. Mol Pharmacol 60:1040-1048.
18. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, and Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47.
19. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, and Ratain MJ (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuranidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582.
20. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, and Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Investig 101:847-854.
21. Jinno H, Saeki M, Saito Y, Tanaka-Kagawa T, Hanioka N, Sai K, Kaniwa N, Ando M, Shirao K, Minami H, et al. (2003) Functional characterization of human UDP-glucuronosyltransferase (UGT) 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 306:688-693.
22. Kurkela M, Garcia-Horsman JA, Luukkanen L, Morsky S, Taskinen J, Baumann M, Kostiainen R, Hirvonen J, and Finel M (2003) Expression and Characterization of Recombinant Human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than the other UGTs and was purified as an active dimeric enzyme. J Biol Chem 278:3536-3544.
23. Lanouette CM, Giacobino JP, Perusse L, Lacaille M, Yvon C, Chagnon M, Kuhne F, Bouchard C, Muzzin P, and Chagnon YC (2001) Association between uncoupling protein 3 gene and obesity-related phenotypes in the Quebec Family Study. Mol Med 7:433-441.
24. Ledermann JA, Leonard P, and Seymour M (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345:145-146.
25. Meech R and Mackenzie PI (1997) UDP-glucuronosyltransferase, the role of the amino terminus in dimerization. J Biol Chem 272:26913-26917.
26. Peters WH, Jansen PL, and Nauta H (1984) The molecular weights of UDP-glucuronyltransferase determined with radiation-inactivation analysis. A molecular model of bilirubin UDP-glucuronyltransferase. J Biol Chem 259:11701-11705.
27. Ramirez J, Iyer L, Journault K, Belanger P, Innocenti F, Ratain MJ, and Guillemette C (2002) In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res (NY) 19:588-594.
28. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, et al. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [see comments] [published erratum appears in Lancet 1998 Nov 14;352(9140):1634]. Lancet 352:1407-1412.
29. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914.
30. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, et al. (1996) Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumors. J Clin Oncol 14:2959-2967.
31. Sargent DJ, Niedzwiecki D, O'Connell MJ, and Schilsky RL (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345:144-145; author reply 146.
32. Schneider S, Roessli D, and Excoffier L (2000) Arlequin: A Software for Population Genetics Data Analysis. Version 2.000. Genetics and Biometry Lab, Department of Anthropology, University of Geneva, Geneva, Switzerland.
33. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, and Verweij J (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4:2747-2754.
34. Stephens M, Smith NJ, and Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
35. Strassburg CP, Vogel A, Kneip S, Tukey RH, and Manns MP (2002) Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 50:851-856.
36. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, and Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752-3757.
37. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, and Strassburg CP (2001) Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 121:1136-1144.
38. Woolley AT, Guillemette C, Li Cheung C, Housman DE, and Lieber CM (2000) Direct haplotyping of kilobase-size DNA using carbon nanotube probes. Nat Biotechnol 18:760-763.
39. Xie R, Mathijssen RH, Sparreboom A, Verweij J, and Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 72:265-275.
40. Zheng Z, Park JY, Guillemette C, Schantz SP, and Lazarus P (2001) Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 93:1411-1418.